AstraZeneca Scheduled to Report Q3 Earnings on October 30
AstraZeneca PLC (AZN) is set to release its third-quarter financial results on Friday, October 30, prior to the market opening. Market analysts have established a consensus earnings per share (EPS) estimate of $1.15 and a revenue projection of approximately $16 billion. The upcoming report follows recent clinical developments, including positive late-stage trial data for a stomach cancer drug that reportedly doubled survival rates. Investors are also monitoring the company's strategic direction regarding potential expansions into cancer vaccine development.
Tickers: $AZN
Topics: EPS estimates oncology research Q3 earnings preview revenue estimates